Take two for QRxPharma
Friday, 27 February, 2009
Sydney-based QRxPharma has begun a comparative pilot study to test the efficacy and safety of its MoxDuo immediate release analgesic in patients with post-operative pain.
Data from the three-arm study will be used to establish the optimal dose regimen and in the design of the company’s planned Phase III trial in patients following total knee replacement surgery.
The study hopes to enrol 45 patients at three US clinical research sites. Each group of patients will be treated every four to six hours over a 48-hour period.
The study will compare the analgesic efficacy and safety profile of MoxDuo against control groups receiving Percocet, and against patient controlled analgesia.
MoxDuo consists of a fixed ratio of morphine and oxycodone. It is intended for the treatment of moderate to severe pain.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
